Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice
Open accessThe DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index; 12 of the 51 sources its claims cite were checked for support.
Abstract
C3 deficiency protects against hippocampal neurodegeneration and cognitive decline in aged APP/PS1 mice despite abundant Aβ plaques.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
10 Valid · 1 Not valid · 23 Not checked · 77 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Consistent with our previous results (5), C3 KO mice had significantly more synaptic puncta than WT mice.”
§ Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice > Results > Partial protection against age-related hippocampal synaptic degeneration in APP/PS1;C3 KO mice
What the sources say
- Partly supportedcites [5] Shi Q, Colodner KJ, Matousek SB, Merry K, Hong S, Kenison JE, Frost JL, Le KX, Li S, Dodart JC, Caldarone BJ, Stevens B, Lemere CA, Complement C3-Deficient Mice Fail to Display Age-Related Hippocampal Decline. J Neurosci 35, 13029– 13042 (2015). 26400934 PMC6605437 sourceExperimental — accuracy not yet measured
Our copy does report significantly higher synaptic puncta density in C3 KO vs WT mice, but only with age and region bounds the citing sentence drops: at P30 there were no genotype differences, at 4 months only presynaptic Vglut2-IR puncta differed (p = 0.0347) with no difference in Homer1 or colocalization, and the full increase (Vglut2 p = 0.002, Homer1 p < 0.0001, colocalization p = 0.0109) appears at 16 months in HC CA3-SR, with similar effects in DG-SM and V1 but explicitly no differences in CA1 (Results, 'Complement-deficient mice do not display age-related synapse loss'; Fig. 2 legend, 'C3 deficiency in neurodegeneration'). The unqualified statement 'C3 KO mice had significantly more synaptic puncta than WT mice' therefore overstates the source by omitting the aged-timepoint and region-specific qualifiers. The supporting evidence for the direction of the effect (and corroborating Golgi spine-density and Western blot synaptic-marker increases at 16 months) is present in the same sections. (LLM, conf=0.70)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Complement activation is elevated in human AD brain, especially in the presence of fibrillar amyloid plaques containing clusters of reactive microglia (8, 9, 11, 12)”
§ Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice > Discussion
What the sources say
- Supportedcites [8] Stoltzner SE, Grenfell TJ, Mori C, Wisniewski KE, Wisniewski TM, Selkoe DJ, Lemere CA, Temporal accrual of complement proteins in amyloid plaques in Down’s syndrome with Alzheimer’s disease. Am J Pathol 156, 489– 499 (2000). 10666378 PMC1850044 source
The paper states that classical complement activation has been observed in AD brain and that compacted amyloid plaques in AD are often associated with activated microglia and complement proteins. Its Discussion further links abundant complement proteins in compacted plaques with activated microglia in AD-type lesions. The indexed passages provide section labels but no page numbers. (LLM, conf=0.86)
- Not checked yetcites [9] Eikelenboom P, Hack CE, Kamphorst W, Rozemuller JM, Distribution pattern and functional state of complement proteins and alpha 1-antichymotrypsin in cerebral beta/A4 deposits in Alzheimer’s disease. Res Immunol 143, 617– 620 (1992). 1455052 source
- Not checked yetcites [11] Veerhuis R, Histological and direct evidence for the role of complement in the neuroinflammation of AD. Curr Alzheimer Res 8, 34– 58 (2011). 21143154 source
- Not checked yetcites [12] Tenner AJ, Complement in Alzheimer’s disease: opportunities for modulating protective and pathogenic events. Neurobiol Aging 22, 849– 861 (2001). 11754992 source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“We recently demonstrated that C3-deficiency spared age-dependent synaptic and neuronal loss in a region-specific manner, and protected against cognitive impairment in normal aging of C57BL/6 mice (5).”
§ Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice > Introduction
What the sources say
- Supportedcites [5] Shi Q, Colodner KJ, Matousek SB, Merry K, Hong S, Kenison JE, Frost JL, Le KX, Li S, Dodart JC, Caldarone BJ, Stevens B, Lemere CA, Complement C3-Deficient Mice Fail to Display Age-Related Hippocampal Decline. J Neurosci 35, 13029– 13042 (2015). 26400934 PMC6605437 source
The section 'Complement-deficient mice do not display age-related HC neuron loss' (p. ~ Results) states that age-dependent, region-specific synapse and neuron loss seen in WT C57BL/6J mice (CA3-SR, DG-SM reduced; CA1 spared) was rescued in aged male C3 KO mice, who had more synaptic puncta, higher SYP density and synaptic protein levels, higher LTP and more CA3 neurons. The section 'Complement C3-deficient mice do not display age-dependent behavioral deficits' states that C3 deficiency significantly protected mice against age-related cognitive decline, and the Summary ('C3 deficiency in neurodegeneration') reiterates that these age-related effects were spared in C3 KO mice. All elements of the citing sentence — C3-deficiency, sparing of age-dependent synaptic and neuronal loss in a region-specific manner, protection against cognitive impairment, and normal aging of C57BL/6 mice — are carried by our copy. (LLM, conf=0.93)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Previously, we reported an age-dependent loss of CA3 neurons in 16 month-old C57BL/6 mice (5).”
§ Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice > Discussion
What the sources say
- Supportedcites [5] Shi Q, Colodner KJ, Matousek SB, Merry K, Hong S, Kenison JE, Frost JL, Le KX, Li S, Dodart JC, Caldarone BJ, Stevens B, Lemere CA, Complement C3-Deficient Mice Fail to Display Age-Related Hippocampal Decline. J Neurosci 35, 13029– 13042 (2015). 26400934 PMC6605437 source
The Results section, “Complement-deficient mice do not display age-related HC neuron loss,” reports significantly fewer CA3 neurons in 16-month-old wild-type mice than at P30. The paper identifies the wild-type mice as C57BL/6J. The 16-month versus 4-month comparison was not significant, so the demonstrated loss is relative to P30. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“16-month-old APP/PS1;C3 KO mice performed significantly better on a learning and memory task than APP/PS1 mice, despite having more cerebral Aβ plaques.”
- Also stated in: § Sparing of cognitive decline in plaque-burdened aged APP/PS1;C3 KO mice · plain
“Reversal learning in APP/PS1;C3 KO mice was similar to that of WT mice and C3 KO mice, and was significantly better than that of APP/PS1 mice on Days 4 and 5”
§ Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice > Abstract
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Sparing of cognitive decline in plaque-burdened aged APP/PS1;C3 KO mice · plain
48 more claims
Create a free account to see all 111 claims and to verify the 39 references still open.
- Probably not a substantial claim. 35
- It may state two separate claims as one. 35
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Actually, inflammation even happens earlier than protein aggregation.”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“increasing evidence demonstrate that immune signaling may not just be a consequence of protein aggregation in the brain, but that it actually causes the buildup of aggregates at the earliest stages of the disease process.15–17”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, IFN-γ-induced C3 expression in an amyloidogenic mouse model reduced plaque load but resulted in increased loss of synapses and cognitive dysfunction [152, 284].”
From Microglia and monocytes in inflammatory CNS disease: integrating phenotype and function (2022) · cites this paper as [284]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These findings align with previous reports suggesting that plaque morphology, rather than total amyloid burden, may be a key factor in neurotoxicity and disease progression and suggest that this could be an important role for plaque‐associated PLCγ2 expressing microglia (Casali et al. 2020; Shi et al. 2017; Yuan et al. 2016).”
From Alzheimer's Protection by PLCγ2 Compacts Plaques, Redistributes Microglia, and Protects Synapses in App NL ‐G‐F Mice (2026) · cites this paper as Shi et al. 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, recent data indicate that microglia and astrocytes coordinate their functions in many ways, both in the healthy and diseased brain [14–21].”
From Crosstalk between astrocytes and microglia results in increased degradation of α-synuclein and amyloid-β aggregates (2021) · cites this paper as [17]
Experimental — accuracy not yet measured
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice > Discussion
“Recently, Hong et al. reported similar Aβ oligomer-induced, complement-mediated and microglia-dependent synaptic loss in young, pre-plaque AD mice that was rescued by the genetic deletion of C1q or C3, or by treatment with a C1qa blocking antibody (8).”
§ Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice > References
“10. Hong S, Beja-Glasser VF, Nfonoyim BM, Frouin A, Li S, Ramakrishnan S, Merry KM, Shi Q, Rosenthal A, Barres BA, Lemere CA, Selkoe DJ, Stevens B, Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 352, 712– 716 (2016). 27033548 PMC5094372”
Citations
Cites
1 retracted
Bialas, A. R., & Stevens, B. (2013) · Nature Neuroscience · doi:10.1038/nn.3560 · Cited by 519
Self-citationRetractedAmyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420 · cited 1×
“Synapse loss is an early and important change in AD brain (41), and hippocampal synapse loss is observed in APP/PS1 mice (28, 29).”
BackgroundTerry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Microglia Sculpt Postnatal Neural Circuits in an Activity and Complement-Dependent Manner
Schafer, D. P., Lehrman, E. K., Kautzman, A. G., Koyama, R., Mardinly, A. R., Yamasaki, R., Ransohoff, R. M., Greenberg, M. E., Barres, B. A., & Stevens, B. (2012) · Neuron · doi:10.1016/j.neuron.2012.03.026 · Cited by 4,089
Self-citationComplement and microglia mediate early synapse loss in Alzheimer mouse models
Hong, S., Beja-Glasser, V. F., Nfonoyim, B. M., Frouin, A., Li, S., Ramakrishnan, S., Merry, K. M., Shi, Q., Rosenthal, A., Barres, B. A., et al. (2016) · Science · doi:10.1126/science.aad8373 · Cited by 3,343
Self-citationThe Classical Complement Cascade Mediates CNS Synapse Elimination
Stevens, B., Allen, N. J., Vazquez, L. E., Howell, G. R., Christopherson, K. S., Nouri, N., Micheva, K. D., Mehalow, A. K., Huberman, A. D., Stafford, B., et al. (2007) · Cell · doi:10.1016/j.cell.2007.10.036 · Cited by 3,313
Self-citationMicroglia promote learning-dependent synapse formation through brain-derived neurotrophic factor
Parkhurst, C. N., Yang, G., Ninan, I., Savas, J. N., Yates, J. R., Lafaille, J. J., Hempstead, B. L., Littman, D. R., & Gan, W.-B. (2013) · Cell · doi:10.1016/j.cell.2013.11.030 · Cited by 2,599 · cited 1×
“Furthermore, mice deficient in BDNF in microglia have deficits in learning andhippocampal synapse formation, indicating thatmicroglial BDNF signaling plays an important role in hippocampal function (60).”
BackgroundSynapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity
DeKosky, S. T., & Scheff, S. W. (1990) · Annals of Neurology · doi:10.1002/ana.410270502 · Cited by 2,376
Cited by
Items 101–200 of 603
TGF-β as a Key Modulator of Astrocyte Reactivity: Disease Relevance and Therapeutic Implications
Luo, J. (2022) · Biomedicines · doi:10.3390/biomedicines10051206 · Cited by 147
Schlepckow, K., Morenas-Rodríguez, E., Hong, S., & Haass, C. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(23)00247-8 · Cited by 114
Self-citationComplement-dependent synapse loss and microgliosis in a mouse model of multiple sclerosis
Hammond, J. W., Bellizzi, M. J., Ware, C., Qiu, W. Q., Saminathan, P., Li, H., Luo, S., Ma, S. A., Li, Y., & Gelbard, H. A. (2020) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2020.03.004 · Cited by 134
Hesse, R., Hurtado, M. L., Jackson, R. J., Eaton, S. L., Herrmann, A. G., Colom-Cadena, M., Tzioras, M., King, D., Rose, J., Tulloch, J., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0847-7 · Cited by 107
New tricks for an ancient system: Physiological and pathological roles of complement in the CNS
Tenner, A. J., Stevens, B., & Woodruff, T. M. (2018) · Molecular Immunology · doi:10.1016/j.molimm.2018.06.264 · Cited by 112
Self-citationHernandez, M. X., Jiang, S., Cole, T. A., Chu, S.-H., Fonseca, M. I., Fang, M. J., Hohsfield, L. A., Torres, M. D., Green, K. N., Wetsel, R. A., et al. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0210-z · Cited by 105
The role of the immune system in Alzheimer’s disease
Wu, K., Zhang, Y.-R., Huang, Y., Dong, Q., Tan, L., & Yu, J. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101409 · Cited by 127
The complement cascade in the regulation of neuroinflammation, nociceptive sensitization, and pain
Warwick, C. A., Keyes, A. L., Woodruff, T. M., & Usachev, Y. M. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101085 · Cited by 124
Michalska, P., & Leon, R. M. (2020) · Antioxidants · doi:10.3390/antiox9080740 · Cited by 119
Complement-Mediated Events in Alzheimer’s Disease: Mechanisms and Potential Therapeutic Targets
Tenner, A. J. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.1901068 · Cited by 108
Human neural stem cell-derived extracellular vesicles mitigate hallmarks of Alzheimer’s disease
Apodaca, L. A., Baddour, A. A. D., Garcia, C., Alikhani, L., Giedzinski, E., Ru, N., Agrawal, A., Acharya, M. M., & Baulch, J. E. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00791-x · Cited by 110
Central Nervous System Responses to Simulated Galactic Cosmic Rays
Cekanaviciute, E., Rosi, S., & Costes, S. V. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113669 · Cited by 100
TREM2 triggers microglial density and age-related neuronal loss
Linnartz‐Gerlach, B., Bodea, L., Klaus, C., Ginolhac, A., Halder, R., Sinkkonen, L., Walter, J., Colonna, M., & Neumann, H. (2019) · Glia · doi:10.1002/glia.23563 · Cited by 104
Nogueras-Ortiz, C. J., Mahairaki, V., Delgado-Peraza, F., Das, D., Avgerinos, K., Eren, E., Hentschel, M., Goetzl, E. J., Mattson, M. P., & Kapogiannis, D. (2020) · Cells · doi:10.3390/cells9071618 · Cited by 106
Bohlson, S. S., & Tenner, A. J. (2023) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101921-035639 · Cited by 115
The evolving role of neuro‐immune interaction in brain repair after cerebral ischemic stroke
Wang, X., Xuan, W., Zhu, Z., Li, Y., Zhu, H., Zhu, L., Fu, D. D., Yang, L., Li, P., & Yu, W. (2018) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13077 · Cited by 108
The complement cascade in Alzheimer’s disease: a systematic review and meta-analysis
Krance, S. H., Wu, C., Zou, Y. Z., Mao, H., Toufighi, S., He, X., Pakosh, M. T., & Swardfager, W. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0536-8 · Cited by 108
Interactions between Tumor Cells, Neurons, and Microglia in the Glioma Microenvironment
Radin, D. P., & Tsirka, S. E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228476 · Cited by 110
Keaney, J., Gasser, J., Gillet, G., Scholz, D., & Kadiu, I. (2019) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-019-09839-0 · Cited by 98
“In mouse models of Alzheimer’s disease (AD) (Hong et al. 2016; Shi et al. 2017) and frontotemporal dementia (FTD) (Lui et al. 2016), elevated levels of complement factors cause early synaptic loss which can be rescued by inhibition or deletion of C1q, C3 or CR3.”
BackgroundGlial Control of Synapse Number in Healthy and Diseased Brain
Lee, E., & Chung, W.-S. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00042 · Cited by 91
TREM2 is required for microglial instruction of astrocytic synaptic engulfment in neurodevelopment
Jay, T. R., von Saucken, V. E., Muñoz, B., Codocedo, J. F., Atwood, B. K., Lamb, B. T., & Landreth, G. E. (2019) · Glia · doi:10.1002/glia.23664 · Cited by 97
Long, H., Zhou, Z.-W., Cheng, Y., Luo, H., Li, F., Xu, S., & Gao, L. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.888989 · Cited by 106
Wertz, M. H., Mitchem, M. R., Pineda, S. S., Hachigian, L. J., Lee, H., Lau, V., Powers, A. E., Kulicke, R., Madan, G. K., Colic, M., et al. (2020) · Neuron · doi:10.1016/j.neuron.2020.01.004 · Cited by 107
Tzioras, M., Daniels, M. J. D., Davies, C., Baxter, P., King, D., McKay, S., Varga, B., Popovic, K., Hernandez, M., Stevenson, A. J., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101175 · Cited by 105
Gollihue, J. L., & Norris, C. M. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101039 · Cited by 93
Metabolic Dysfunction in Alzheimer’s Disease: From Basic Neurobiology to Clinical Approaches
Clarke, J. R., Ribeiro, F. C., Frozza, R. L., De Felice, F. G., & Lourenco, M. V. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179911 · Cited by 87
Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas
Zeng, J., Li, X., Sander, M., Zhang, H., Yan, G., & Lin, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.721830 · Cited by 97
Molecular Mechanisms of Synaptotoxicity and Neuroinflammation in Alzheimer’s Disease
Marttinen, M., Takalo, M., Natunen, T., Wittrahm, R., Gabbouj, S., Kemppainen, S., Leinonen, V., Tanila, H., Haapasalo, A., & Hiltunen, M. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00963 · Cited by 88
The Cross-Talk Between the Dopaminergic and the Immune System Involved in Schizophrenia
Vidal, P. M., & Pacheco, R. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00394 · Cited by 86
Luchena, C., Zuazo-Ibarra, J., Alberdi, E., Matute, C., & Capetillo-Zarate, E. (2018) · Mediators of Inflammation · doi:10.1155/2018/2530414 · Cited by 82
Han, X., Xu, T., Ding, C., Wang, D., Yao, G., Chen, H., Fang, Q., Hu, G., & Sun, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00867-y · Cited by 96
Ca2+, Astrocyte Activation and Calcineurin/NFAT Signaling in Age-Related Neurodegenerative Diseases
Sompol, P., & Norris, C. M. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00199 · Cited by 82
Microglia-neuron interactions in the models of neuropathic pain
Tozaki‐Saitoh, H., & Tsuda, M. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.08.016 · Cited by 89
Korai, S. A., Ranieri, F., Lazzaro, V. D., Papa, M., & Cirillo, G. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.587771 · Cited by 109
Scott-Hewitt, N., Mahoney, M., Huang, Y., Korte, N., Yvanka de Soysa, T., Wilton, D. K., Knorr, E., Mastro, K., Chang, A., Zhang, A., et al. (2024) · Cell · doi:10.1016/j.cell.2024.05.058 · Cited by 85
Self-citationKamila, P., Kar, K., Chowdhury, S., Chakraborty, P., Dutta, R., S, S., Singh S, A., & Prajapati, B. G. (2025) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2025.05.005 · Cited by 90
“Neurode-generative disorders share common hallmarks, including regional brain vulnerability, chronic inflammation, and the accumulation of misfolded proteins (Shi et al., 2017).”
Self-citationHaure-Mirande, J.-V., Wang, M., Audrain, M., Fanutza, T., Kim, S. H., Heja, S., Readhead, B., Dudley, J. T., Blitzer, R. D., Schadt, E. E., et al. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0255-6 · Cited by 84
Simon, E., Obst, J., & Gomez-Nicola, D. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2018.01.059 · Cited by 83
Tassoni, A., Farkhondeh, V., Itoh, Y., Itoh, N., Sofroniew, M. V., & Voskuhl, R. R. (2019) · Scientific Reports · doi:10.1038/s41598-019-46232-6 · Cited by 79
Pekna, M., & Pekny, M. (2021) · Cells · doi:10.3390/cells10071812 · Cited by 87
Complement System in Alzheimer’s Disease
Shah, A., Kishore, U., & Shastri, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413647 · Cited by 73
The Gut Microbiome as a Regulator of the Neuroimmune Landscape
Yu, L. W., Agirman, G., & Hsiao, E. Y. (2022) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101320-014237 · Cited by 75
The Complement System in the Central Nervous System: From Neurodevelopment to Neurodegeneration
Chen, Y., Chu, J. M. T., Chang, R. C., & Wong, G. T. C. (2022) · Biomolecules · doi:10.3390/biom12020337 · Cited by 84
Liu, B., Hinshaw, R. G., Le, K. X., Park, M.-A., Wang, S., Belanger, A. P., Dubey, S., Frost, J. L., Shi, Q., Holton, P., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-48615-1 · Cited by 73
Self-citationXie, L., Zhang, N., Zhang, Q., Li, C., Sandhu, A. F., III, G. W., Lin, S., Lv, P., Liu, Y., Wu, Q., et al. (2020) · Aging · doi:10.18632/aging.103663 · Cited by 48
Neuron-astrocyte omnidirectional signaling in neurological health and disease
Pathak, D., & Sriram, K. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1169320 · Cited by 77
Neurons and Microglia; A Sickly-Sweet Duo in Diabetic Pain Neuropathy
Rajchgot, T., Thomas, S. C., Wang, J.-C., Ahmadi, M., Balood, M., Crosson, T., Dias, J. P., Couture, R., Claing, A., & Talbot, S. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00025 · Cited by 78
Molecular mechanisms underlying microglial sensing and phagocytosis in synaptic pruning
Huo, A., Wang, J., Li, Q., Li, M., Qi, Y., Yin, Q., Luo, W., Shi, J., & Cong, Q. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.385854 · Cited by 77
Targeting Microglia in Alzheimer’s Disease: Pathogenesis and Potential Therapeutic Strategies
Sun, Z., Zhang, X., So, K.-F., Jiang, W., & Chiu, K. (2024) · Biomolecules · doi:10.3390/biom14070833 · Cited by 71
Yang, H., Oh, C.-K., Amal, H., Wishnok, J. S., Lewis, S., Schahrer, E., Trudler, D., Nakamura, T., Tannenbaum, S. R., & Lipton, S. A. (2022) · Science Advances · doi:10.1126/sciadv.ade0764 · Cited by 70
Gedam, M., Comerota, M. M., Propson, N. E., Chen, T., Jin, F., Wang, M. C., & Zheng, H. (2023) · Journal of Clinical Investigation · doi:10.1172/jci167501 · Cited by 76
Discovery and Validation of Key Biomarkers Based on Immune Infiltrates in Alzheimer’s Disease
Liu, Z., Li, H., & Pan, S. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.658323 · Cited by 75
Tan, X.-X., Qiu, L.-L., & Sun, J. (2021) · BioMed Research International · doi:10.1155/2021/3883204 · Cited by 74
Audrain, M., Haure-Mirande, J.-V., Wang, M., Kim, S. H., Fanutza, T., Chakrabarty, P., Fraser, P., St George-Hyslop, P. H., Golde, T. E., Blitzer, R. D., et al. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0258-3 · Cited by 68
The Role of Astrocytes in Synapse Loss in Alzheimer's Disease: A Systematic Review
Hulshof, L. A., van Nuijs, D., Hol, E. M., & Middeldorp, J. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.899251 · Cited by 64
Modulation of C5a–C5aR1 signaling alters the dynamics of AD progression
Carvalho, K., Schartz, N. D., Balderrama-Gutierrez, G., Liang, H. Y., Chu, S., Selvan, P., Gómez-Arboledas, Á., Petrisko, T. J., Fonseca, M. I., Mortazavi, A., et al. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02539-2 · Cited by 64
The Importance of Complement-Mediated Immune Signaling in Alzheimer’s Disease Pathogenesis
Batista, A. F., Khan, K. A., Papavergi, M.-T., & Lemere, C. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25020817 · Cited by 65
Self-citationLei, W., Cheng, Y., Liu, X., Gao, J., Zhu, Z., Ding, W., Xu, X., Li, Y., Ling, Z., Jiang, R., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1582119 · Cited by 68
Györffy, B. A., Tóth, V., Török, G., Gulyássy, P., Kovács, R. Á., Vadászi, H., Micsonai, A., Tóth, M. E., Sántha, M., Homolya, L., et al. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03468-0 · Cited by 70
Zhang, H., Jiang, W., Zhao, Y., Song, T., Xi, Y., Han, G., Jin, Y., Song, M., Bai, K., Zhou, J., et al. (2022) · Nano Letters · doi:10.1021/acs.nanolett.2c00191 · Cited by 65
Lee, C., Chang, C., Lin, C., Lai, H., Kao, Y.-H., Cheng, S., Chen, H., Liao, Y., Faivre, É., Buée, L., et al. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1030-z · Cited by 66
Hamilton, L. K., Moquin-Beaudry, G., Mangahas, C. L., Pratesi, F., Aubin, M., Aumont, A., Joppé, S. E., Légiot, A., Vachon, A., Plourde, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29506-y · Cited by 66
Bourel, J., Planche, V., Dubourdieu, N., Oliveira, A., Séré, A., Ducourneau, E.-G., Tible, M., Maitre, M., Lesté-Lasserre, T., Nadjar, A., et al. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105533 · Cited by 58
The Role of Glial Cells in Synaptic Dysfunction: Insights into Alzheimer's Disease Mechanisms
Yu, Y., Chen, R., Mao, K., Deng, M., & Li, Z. (2023) · Aging and Disease · doi:10.14336/ad.2023.0718 · Cited by 66
Hinkle, J. J., Olschowka, J. A., Love, T. M., Williams, J. P., & O’Banion, M. K. (2019) · Scientific Reports · doi:10.1038/s41598-019-55366-6 · Cited by 61
Xi, Y., Zhang, Y., Zhou, Y., Liu, Q., Chen, X., Liu, X., Grune, T., Shi, L. S., Hou, M., & Liu, Z. (2022) · Redox Biology · doi:10.1016/j.redox.2022.102595 · Cited by 65
Complement-mediated synapse loss in Alzheimer’s disease: mechanisms and involvement of risk factors
Wen, L., Bi, D., & Shen, Y. (2023) · Trends in Neurosciences · doi:10.1016/j.tins.2023.11.010 · Cited by 71
The impact of astrocytic NF-κB on healthy and Alzheimer’s disease brains
Huat, T. J., Camats‐Perna, J., Newcombe, E. A., Onraet, T., Campbell, D., Sucic, J. T., Martini, A. C., Forner, S., Mirzaei, M., Poon, W. W., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-65248-1 · Cited by 74
Exercise prevents obesity-induced cognitive decline and white matter damage in mice
Graham, L. C., Grabowska, W. A., Chun, Y., Risacher, S. L., Philip, V. M., Saykin, A. J., Rizzo, S. J. S., & Howell, G. R. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.03.018 · Cited by 59
The role of glia in protein aggregation
Li, Q., & Haney, M. S. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105015 · Cited by 52
The complement system in neurodegenerative diseases
Nimmo, J., Byrne, R. A. J., Daskoulidou, N., Watkins, L. M., Carpanini, S. M., Zelek, W. M., & Morgan, B. P. (2024) · Clinical Science · doi:10.1042/cs20230513 · Cited by 61
Understanding microglial diversity and implications for neuronal function in health and disease
De Schepper, S., Crowley, G., & Hong, S. (2021) · Developmental Neurobiology · doi:10.1002/dneu.22777 · Cited by 57
Self-citationDelila, L., Wu, Y., Nebie, O., Widyaningrum, R., Chou, M., Devos, D., & Burnouf, T. (2020) · Platelets · doi:10.1080/09537104.2020.1849603 · Cited by 54
Complement cascade functions during brain development and neurodegeneration
Fatoba, O., Itokazu, T., & Yamashita, T. (2021) · FEBS Journal · doi:10.1111/febs.15772 · Cited by 61
Gómez-Arboledas, Á., Carvalho, K., Balderrama-Gutierrez, G., Chu, S., Liang, H. Y., Schartz, N. D., Selvan, P., Petrisko, T. J., Pan, M. A., Mortazavi, A., et al. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01416-6 · Cited by 61
Chandra, S., Di Meco, A., Dodiya, H. B., Popovic, J., Cuddy, L. K., Weigle, I. Q., Zhang, X., Sadleir, K., Sisodia, S. S., & Vassar, R. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00635-2 · Cited by 58
Zhang, Q., Zhang, J., Ye, J., Li, X., Liu, H., Ma, X., Wang, C., He, K., Zhang, W., Ji, Y., et al. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00485-w · Cited by 62
Developmental roles of microglia: A window into mechanisms of disease
Anderson, S., & Vetter, M. L. (2018) · Developmental Dynamics · doi:10.1002/dvdy.1 · Cited by 54
Vandendriessche, C., Balusu, S., Van Cauwenberghe, C., Brkic, M., Pauwels, M., Plehiers, N., Bruggeman, A., Dujardin, P., Van Imschoot, G., Van Wonterghem, E., et al. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01245-z · Cited by 56
Peterson, S. L., Li, Y., Sun, C., Wong, K. A., Leung, K. S., de Lima, S., Hanovice, N. J., Yuki, K., Stevens, B., & Benowitz, L. I. (2021) · Journal of Neuroscience · doi:10.1523/jneurosci.0555-21.2021 · Cited by 53
Self-citationThe complement system in neurodegenerative and inflammatory diseases of the central nervous system
Negro‐Demontel, M. L., Maleki, A. F., Reich, D. S., & Kemper, C. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1396520 · Cited by 63
Li, J., Wang, H., Du, C., Jin, X., Geng, Y., Han, B., Ma, Q., Li, Q., Wang, Q., Guo, Y., et al. (2020) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2020.07.004 · Cited by 55
The Post-amyloid Era in Alzheimer's Disease: Trust Your Gut Feeling
Osorio, C., Kanukuntla, T., Diaz, E., Jafri, N., Cummings, M., & Sfera, A. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00143 · Cited by 49
Borucki, D. M., Toutonji, A., Couch, C., Mallah, K., Rohrer, B., & Tomlinson, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.566892 · Cited by 50
Cong, Q., Soteros, B. M., Huo, A., Li, Y., Tenner, A. J., & Sia, G. M. (2022) · Glia · doi:10.1002/glia.24114 · Cited by 49
Exploring the dual character of metformin in Alzheimer's disease
Ning, P., Luo, A., Mu, X. L., Xu, Y., & Li, T. X. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.108966 · Cited by 53
Wang, Y., Zhou, Y., Jiang, L. H., Wang, S., Zhu, L., Zhang, S., Yang, H., He, Q., Liu, L., Xie, Y., et al. (2023) · Experimental Neurology · doi:10.1016/j.expneurol.2023.114371 · Cited by 58
Brain Inflammation Connects Cognitive and Non-Cognitive Symptoms in Alzheimer’s Disease
Selles, M. C., Oliveira, M. M., & Ferreira, S. T. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179925 · Cited by 50
Schmitz, T. W., Soreq, H., Poirier, J., & Spreng, R. N. (2020) · The Journal of Neuroscience · doi:10.1523/jneurosci.1184-19.2019 · Cited by 45
Effect of APOE alleles on the glial transcriptome in normal aging and Alzheimer’s disease
Serrano-Pozo, A., Li, Z., Noori, A., Nguyen, H. N., Mezlini, A., Li, L., Hudry, E., Jackson, R. J., Hyman, B. T., & Das, S. (2021) · Nature Aging · doi:10.1038/s43587-021-00123-6 · Cited by 49
Brain–immune interaction mechanisms: Implications for cognitive dysfunction in psychiatric disorders
Zhao, F., Li, B., Yang, W., Ge, T., & Cui, R. (2022) · Cell Proliferation · doi:10.1111/cpr.13295 · Cited by 56
The role of the complement system in Multiple Sclerosis: A review
Saez-Calveras, N., & Stüve, O. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.970486 · Cited by 57
Tillmon, H., Soteros, B. M., Shen, L., Cong, Q., Wollet, M., General, J., Chin, H., Lee, J. B., Carreno, F. R., Morilak, D. A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54007-5 · Cited by 68
Neuroinflammation is increased in the parietal cortex of atypical Alzheimer’s disease
Boon, B. D. C., Hoozemans, J. J. M., Lopuhaä, B., Eigenhuis, K. N., Scheltens, P., Kamphorst, W., Rozemuller, A. J. M., & Bouwman, F. H. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1180-y · Cited by 48
Microglia: The Brain's First Responders.
Bilbo, S. D., & Stevens, B. (2017) · PubMed Central · Cited by 61
Self-citationBevan, R. J., Hughes, T. R., Williams, P. A., Good, M. A., Morgan, B. P., & Morgan, J. E. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-01094-2 · Cited by 49
Chen, M., Hu, Z., Ding, J., Du, R., & Hu, G. (2021) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2021.04.003 · Cited by 47
BAD-mediated neuronal apoptosis and neuroinflammation contribute to Alzheimer's disease pathology
Zhang, L., Qian, Y., Li, J., Zhou, X., Xu, H. J., Yan, J., Xiang, J., Yuan, X., Sun, B., Sisodia, S. S., et al. (2021) · iScience · doi:10.1016/j.isci.2021.102942 · Cited by 57
Pal, A., Rani, I., Pawar, A. T., Picozza, M., Rongioletti, M. C. A., & Squitti, R. (2021) · Biomolecules · doi:10.3390/biom11111598 · Cited by 50
Stress and Alzheimer’s disease: A senescence link?
Lyons, C. E., & Bartolomucci, A. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.05.010 · Cited by 56
Metadata
- Authors
- Shi, Q., Chowdhury, S., Ma, R., Le, K. X., Hong, S., Caldarone, B. J., Stevens, B., & Lemere, C. A.
- Affiliations
- Brigham and Women's Hospital (US)
- Boston Children's Hospital (US)
- Corresponding author
- Lemere, Cynthia A.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2017-05-31
- Volume
- 9
- Issue
- 392
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC6936623
- OpenAlex
- W2618794795
- Semantic Scholar
- 9b3f6a14369dd65bfc394e92ccb26bd20b83ccd0
- Cited by
- 593
- References
- 70
- Citations by year
- 2026: 47 · 2025: 72 · 2024: 75 · 2023: 71 · 2022: 66 · 2021: 88 · 2020: 64 · 2019: 50 · 2018: 43 · 2017: 17
- FWCI
- 35.19
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Aging (award298479, R21 AG044713)
- BrightFocus Foundation (award298478, A2016425F)
- Fidelity Biosciences (award298481, (F-PRIME), award298470, F-PRIME)
- Edward R and Anne G Lefler (award298482, Fellowship)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
- Keywords
- complement C3, complement system, neurodegeneration, Alzheimer's disease, APP/PS1 mice, amyloid plaques, microglia, synaptic loss, neuronal loss, aging, glial response
- MeSH terms
- Aging, Animals, Astrocytes, Complement C3, Gliosis, Hippocampus, Mice, Inbred C57BL, Nerve Degeneration, Solubility, Synapses, Cytokines, Amyloid beta-Protein Precursor, Mice, Knockout, Presenilin-1, Plaque, Amyloid, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.